A randomized, double-blind, placebo- and active-controlled, parallel group, 6-week study to evaluate the effect of multiple doses of Flutiform [formoterol/fluticasone propionate] 250/10 microgram HFA [hydrofluoroalkane] pMDI [pressurised metered-dose inhaler] twice daily, Flutiform 100/10 microgram HFA pMDI twice daily, prednisone and placebo on the hypothalamic-pituitary-adrenal axis in adult subjects with mild to moderate asthma

Trial Profile

A randomized, double-blind, placebo- and active-controlled, parallel group, 6-week study to evaluate the effect of multiple doses of Flutiform [formoterol/fluticasone propionate] 250/10 microgram HFA [hydrofluoroalkane] pMDI [pressurised metered-dose inhaler] twice daily, Flutiform 100/10 microgram HFA pMDI twice daily, prednisone and placebo on the hypothalamic-pituitary-adrenal axis in adult subjects with mild to moderate asthma

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2008

At a glance

  • Drugs Formoterol/fluticasone propionate; Prednisone
  • Indications Asthma
  • Focus Pharmacodynamics
  • Sponsors SkyePharma AG
  • Most Recent Events

    • 30 Nov 2008 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
    • 18 Aug 2008 Planned end date changed from 1 Jul 2008 to 1 Sep 2008 as reported by ClinicalTrials.gov.
    • 18 Aug 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top